AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
ORLANDO -- Chemotherapy that is given before surgery improves optimal cytoreduction rates in patients with advanced epithelial ovarian cancer, a retrospective comparative study suggests.
Most women with advanced epithelial ovarian cancer receive initial surgery followed by intensive platinum/taxane combination chemotherapy.
The goal is optimal cytoreduction ("debulking") defined as gross residual disease of less than 1 cm following maximal surgical effort, but this goal is only achieved about half of the time.
Patients were selected for initial chemotherapy based upon disease extent estimated on preoperative CT scan or unacceptable medical comorbidities.
Initial chemotherapy was given to patients with disease judged unlikely to achieve an optimal result with resection.
In addition, patients medically unfit for surgery or patients who refused surgery secondary to the risks of transfusion or ostomy were given initial chemotherapy. Rates of hemorrhage, bowel resection, and postoperative surgical morbidity were similar in the two groups, as were chemotherapy regimens, Dr. Elise Everett said at the annual meeting of the South Atlantic Association of Obstetricians and Gynecologists.
The rate of optimal debulking was 85% in 98 advanced epithelial ovarian cancer patients who received initial chemotherapy prior to their surgery, ...
Source: HighBeam Research, Initial chemotherapy beneficial in epithelial ovarian cancer.(News)